cerrar
Tagged with PR

3 US Pharma Mid-Cap Execs to Know
The US heads for three leading international mid-cap innovators – Japanese firms Eisai and Kyowa Kirin and Danish outfit Lundbeck – explain their…

Axel B Müller – Managing Director, Intergenerika,…
Intergenerika’s Dr Axel B. Müller makes an impassioned case against the introduction of a reference pricing system in Switzerland, arguing that it…

Paying for Cell & Gene Therapy in the USA: Is the Future…
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under…

Has the Time Truly Come for Trudeau’s ‘National Pharmacare’…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the…

Market Access in Switzerland: Reimbursement Delays for 76% of New…
Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…

US Elections: Biden & Trump’s Unworkable Drug Pricing…
In the aftermath of the fiery first presidential debate between incumbent Donald Trump and Democratic Party rival Joe Biden, we round up the latest on…

This Could Get Messy: Trump’s New ‘Most Favoured Nation’…
Regular PharmaBoardroom contributor Brendan Shaw weighs in on the potential implications for US pharma of President Donald Trump’s latest executive…

Italy Takes Global Lead in Pricing Transparency by Forcing Pharma…
In July 2020, Italy became the first country in the world to mandate pharma companies to disclose data surrounding public subsidies received for the…

Supporting Value-Based Purchasing in the US Through Changes in…
Michael Ciarametaro, VP for Research at the US National Pharmaceutical Council (NPC), outlines issues surrounding the outdated Medicaid Best Price…

China’s 3rd Drug Procurement Round: A Bloodbath for…
Since the Chinese government unrolled an unprecedented volume-based procurement initiative for essential drugs used in the public hospital system in…

Sanofi Buys Principia for USD 3.7 Billion as Part of Specialty…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full…

The Long Read: Belgium – The Multifaceted
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France,…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here